Small cell lung cancer tumor-associated antigens (SCLC TAAs)

Small cell lung cancer (SCLC) tumor-associated antigens (TAAs) are a heterogeneous group of cell-surface molecules, including proteins and glycolipids, that are significantly overexpressed on SCLC cells compared to normal tissues. These antigens, such as Delta-like ligand 3 (DLL3), B7-H3 (CD276), Seizure related 6 homolog (SEZ6), and Trop-2, are often linked to the neuroendocrine differentiation and aggressive growth characteristics of this malignancy (Source: Journal of Hematology & Oncology, 2023). They serve as critical therapeutic targets for novel modalities designed to overcome the limitations of traditional chemotherapy, specifically through the use of antibody-drug conjugates (ADCs) and bispecific T-cell engagers (BiTEs) (Source: Nature Reviews Clinical Oncology, 2024). For instance, Tarlatamab is a BiTE that targets DLL3 to facilitate T-cell mediated destruction of tumor cells, while Ifinatamab deruxtecan is an ADC targeting B7-H3 to deliver a potent topoisomerase I inhibitor (Source: New England Journal of Medicine, 2023). The clinical success of targeting these antigens depends heavily on the specificity of their expression, as low-level presence in healthy tissues can lead to on-target off-tumor toxicities such as pneumonitis or neurotoxicity (Source: Lancet Oncology, 2022). Additionally, the identification of these antigens has led to the development of predictive biomarkers, such as DLL3 immunohistochemistry, to better select patients for targeted interventions (Source: Journal of Clinical Oncology, 2023).

Other names

SCLC antigensSmall cell lung cancer antigensSCLC-associated antigensNeuroendocrine tumor-associated antigens

Targeted immunotherapy and cytotoxic delivery via bispecific T-cell engagers (BiTEs), antibody-drug conjugates (ADCs), and chimeric antigen receptor (CAR) T-cells.